On May 17, 2022 Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, reported that Rob Ross, M.D., chief executive officer, will participate in two upcoming investor conferences (Press release, Surface Oncology, MAY 17, 2022, View Source [SID1234614743]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A fireside chat at the UBS Global Healthcare Conference on Monday, May 23, 2022, at 2:45 p.m. ET in New York City.

A corporate presentation at the H.C. Wainwright Global Investment Conference. The prerecorded presentation will become available on-demand starting Tuesday, May 24, 2022, at 7 a.m. ET.
Archived webcasts of the fireside chat and on-demand corporate presentation will be accessible from the Events & Presentations page of the company’s website.